Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Autobahn Therapeutics to Participate in Upcoming Investor Conferences


Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in two upcoming investor conferences:

Evercore ISI's 2024 Emerging Private Biotech Conference
Company Presentation: Thursday, February 29, 2024, at 1:05 p.m. ET
Location: Virtual

TD Cowen's 44th Annual Health Care Conference
Investor Meetings: Wednesday, March 6, 2024
Location: Marriott Copley Place, Boston, MA

About Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neurodegenerative clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company's pipeline is led by ABX-002, a thyroid hormone receptor beta (TR?) agonist, being developed as a potential adjunctive treatment for people with MDD, including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.


These press releases may also interest you

at 20:15
AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer's Disease (POLARIS-AD)
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...

at 19:34
Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRAtm
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective...

at 16:48
Marc Dubrick and Lisa Becharas Win St. Anthony's Triathlon
Marc Dubrick and Lisa Becharas are bringing victories home to Boulder, Colorado, after winning their first St. Anthony's Triathlon along St. Petersburg's scenic downtown waterfront. The winners, who are teammates on The Real Triathlon Squad, raced a...

at 16:30
CYTALUX Real-World Experience Presented at the American Association for Thoracic Surgery 104th Annual Meeting
Nicholas Baker, M.D., Director of Robotic Thoracic Surgery at the University of Pittsburgh Medical Center (UPMC) Passavant, presented key findings from independent research at the 104th Annual Meeting of the American Association for Thoracic Surgery...

at 15:40
Brooks Breland Named Leading Lawn and Plant Health Care Expert
Sexton Lawn & Landscapes is thrilled to announce the appointment of Brooks Breland as the leading Lawn and Plant Health Expert. In this role, Breland will...

at 12:00
OBiO Technology will showcase at American Society of Gene & Cell Therapy
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...

More news about Health...


News published on and distributed by: